Vilon
Vilon is a synthetic dipeptide bioregulator (Lys-Glu, or KE) developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. It is studied primarily as a thymus and immune-system regulator, with a secondary interest in its longevity and gene-expression effects. It is used in research contexts to explore restoration of age-related immune decline.
Researchers and individuals interested in immune-modulation and thymic bioregulation, particularly in the context of age-related immune decline.
Vilon is one of the shortest of the Khavinson 'bioregulator' peptides, a synthetic dipeptide composed of lysine and glutamic acid (Lys-Glu, abbreviated KE). It was derived from work on thymus-gland peptide extracts, with the hypothesis that very short peptide fragments could carry the regulatory signal of larger tissue peptides. Mechanistically, it is proposed to act at the level of gene expression: the small charged dipeptide is thought to interact with DNA and chromatin, potentially modulating transcription in thymocytes, lymphocytes, and other cell types, though the precise molecular details remain incompletely characterized and debated.
In animal and cell-culture studies, Khavinson's group reported effects on immune-cell function, restoration of some age-related immune parameters, and changes in the expression of genes tied to cell proliferation and differentiation. Much of the supporting literature originates from a single research program and has seen limited independent replication in Western peer-reviewed journals, so the strength of evidence should be viewed cautiously. There is no established human pharmacokinetic profile, and dosing in the literature spans a wide microgram-to-milligram range.
Vilon is not approved by the FDA for any use; it is an unapproved research compound, not a medicine, and any use should be considered experimental and undertaken only with qualified physician guidance.
Dosed in micrograms, not milligrams. Documented injectable protocols run roughly 67-670 mcg subcutaneously once daily in short ~10-day courses, repeated a few times per year; a conservative start is ~100 mcg/day. (Some sources quote 5-10 mg for oral/nasal bulk forms — that does not apply to the injectable.)
Immune and general-wellbeing effects, where reported, are described gradually over a full 10-day course rather than acutely.
Frequently paired with other Khavinson bioregulators such as Thymalin (immune) or Epithalon (pineal/longevity), or run standalone.
Log every dose, count every vial, and verify your batches — free in the goodtides app.
This page is educational reference material about compounds studied in research settings. It is not medical advice, and nothing here is a recommendation to buy, possess, or use any compound. Research findings described are from published literature; individual compounds may not be approved for human use. Talk to a licensed clinician about anything that affects your health.